在4.5至24小时内治疗急性缺血性中风的基:随机对照试验的元分析
Zixin Wang1,2, Jiamin Li1,2, Xinyi Wang1,2
1Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China (Z.W., Jiamin Li, X.W., B.Y., Jiameng Li, Q.M.).
Stroke
|October 13, 2025
概括
甲 (TNK) 改善了在24小时内治疗的急性缺血性中风患者的功能结果和再通道化. 当内血管血栓切除术 (EVT) 不存在时,它提供了更大的好处,作为一种替代的再输注策略.
科学领域:
- 神经学 神经学
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 在4.5至24小时之间接受治疗的急性缺血性中风患者中,基酶 (TNK) 的疗效尚不确定.
- 以前的元分析没有区分带有和没有内血管血栓切除术 (EVT) 的环境,这可能会混TNK的净效应.
研究的目的:
- 为了评估尖性缺血性中风患者的基酶 (TNK) 的益处,在4.5至24小时内治疗.
- 为了区分TNK在临床环境中的有效性,允许内血管血栓切除术 (EVT) 和不允许内血管血栓切除术 (EVT).
主要方法:
- 一个随机效应的四个随机对照试验的元分析,涉及1278名患者.
- 静脉注射TNK (0.25 mg/kg) 与标准治疗/安慰剂的比较.
- 根据EVT可用性 (非EVT与EVT允许的设置) 进行了子组分析.
主要成果:
- 与对照人群相比,TNK显著改善了良好的功能结果 (OR, 1.34) 和再通道化 (OR, 3.30).
- 在非EVT环境中,TNK显著改善了优秀的 (OR,1.46) 和良好的 (OR,1.50) 功能结果,以及早期的神经改善 (OR,3.21).
- 在EVT允许的环境中,TNK主要改善了再通道化 (OR,2.36);没有观察到症状性内出血或死亡率的显著增加.
结论:
- 甲 (TNK) 在延长的24小时窗口内增强急性缺血性中风患者的功能结果和再通道化.
- TNK是一种有价值的替代性反策略,特别是在资源有限的环境中,EVT无法获得.
- 治疗不会增加症状性内出血或90天死亡的风险.
相关概念视频
Acute Coronary Syndrome IV: Interprofessional Care
219
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
219
Acute Coronary Syndrome I: Introduction
804
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
804
Cardiopulmonary Resuscitation IV: Pharmacological Management
655
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
655
Clot Retraction and Fibrinolysis
8.4K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
8.4K
Acute Coronary Syndrome III: Diagnostic Studies
213
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
213
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
794
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
794


